Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CSL 324

Drug Profile

CSL 324

Alternative Names: Anti-CSF3 Therapeutic Antibody; Anti-G-CSFR mAb; CSL324; CSL324 G-CSFR; G-CSF antagonists - CSL

Latest Information Update: 13 Sep 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator MuriGen Therapeutics; Zenyth Therapeutics
  • Developer CSL
  • Class Anti-inflammatories; Antirheumatics; Monoclonal antibodies; Skin disorder therapies
  • Mechanism of Action Granulocyte colony stimulating factor inhibitors; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Hidradenitis suppurativa; Inflammation; Palmoplantar pustulosis; Rheumatoid arthritis

Most Recent Events

  • 20 Aug 2019 CSL 324 is still in phase I development for Inflammation (In volunteers) and Rheumatoid arthritis (In volunteers) in Australia (CSL Behring pipeline, August 2019)
  • 28 Jul 2019 No recent reports of development identified for phase-I development in Inflammation(In volunteers) in Australia (IV, Infusion)
  • 28 Jul 2019 No recent reports of development identified for phase-I development in Rheumatoid-arthritis(In volunteers) in Australia (IV, Infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top